Preclinical News and Research

RSS
Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Researchers develop new pneumococcal vaccine through novel discovery approach

Researchers develop new pneumococcal vaccine through novel discovery approach

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences receives new U. S. Patent for chemical compound screening

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

CTI's fourth quarter net loss increases to $34.1 million

CTI's fourth quarter net loss increases to $34.1 million

AMT 2010 total net income increases to EUR 1.4 million

AMT 2010 total net income increases to EUR 1.4 million

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Aeolus receives BARDA contract for AEOL 10150 drug development against ARS

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

Oncolytics' REOLYSIN/gemcitabine combination Phase 2 pancreatic cancer trial meets primary endpoint

BioTime to merge Glycosan with OrthoCyte

BioTime to merge Glycosan with OrthoCyte

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.